Achieve Life Sciences ACHV Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Achieve Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Achieve Life Sciences's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Achieve Life Sciences's additional paid-in capital?
- Achieve Life Sciences (ACHV) reported additional paid-in capital of $280.95M in Q1 2026.
- How has Achieve Life Sciences's additional paid-in capital changed year-over-year?
- Achieve Life Sciences's additional paid-in capital increased by 22.9% year-over-year, from $228.58M to $280.95M.
- What is the long-term trend for Achieve Life Sciences's additional paid-in capital?
- Over 5 years (2020 to 2025), Achieve Life Sciences's additional paid-in capital has grown at a 23.6% compound annual growth rate (CAGR), from $97.64M to $281.61M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.